Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Coliseum Capital Keeps Increasing Stake in Accuride

Coliseum Capital’s Christopher Shackelton And Adam Gray are still bullish on Accuride Corporation (NYSE:ACW). In a recent Form 4 filing with the Securities and Exchange Commision, the fund has reported the acquisition of a little over 270 thousand shares. The transactions have been conducted at a price of $3.3 and $3.32 per share, with Coliseum currently holding 8,197,433 shares.

Accuride Logo

James Dinan‘s York Capital Management has also been betting on Accuride Corporation, with the fund holding approximately 2 million shares reportedly worth a little over $10 million. Roger Keith Long, the manager of Otter Creek Management, has actually been reducing his fund’s exposure to this stock. Otter Creek Management decreased their holding of Accuride Corporation by 280 thousand shares and currently holds 1 million shares worth a little over $5 million. One fund that has liquidated their investment in Accuride is Fine Capital Partners, managed by Debra Fine. The fund previously owned 860 thousand shares.

In the first half of 2013, Accuride’s stock registered a significant advance, from $3.3 per share in January to $6.88 – the July high. Since then the share price has been in a downtrend, currently at $3.36. The stock has a beta of 3.27, making it a fairly volatile one, and does to pay a dividend.

Accuride has recently reported their financial performance for the third quarter of 2013. According the SEC filing, the company registered revenues of $155 million, a 17% decrease compared to the same period last year. Accuride also reported a loss per share of $0.39. For the current quarter, market participants expect revenues of $141 million and a loss per share of $0.16. Analysts are fairly bullish on this stock, recommending it as a Buy and Strong Buy and having set a price target of approximately $4.13 per share.

Disclosure: none

Recommended reading:

Jeffrey Eberwein, Lone Star Increase Stake in Crossroads Systems

Altai Capital Limits Exposure to Intralinks Holdings

Mario Gabelli, Gamco Slightly Increase Holding in Media General

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!